Kabra Drugs Surges 578% Profit Amidst Major Turnaround

Kabra Drugs Limited has demonstrated significant turnaround momentum, reporting a 578% year-over-year surge in Profit After Tax (PAT) for the quarter ended December 31, 2025. The company's unaudited financial results reveal a robust performance, with revenue climbing to ₹30.42 crore, a 53.9% increase from the previous quarter. This marks a substantial recovery from a period of nil revenue in the same quarter last year.

Accompanying these strong financial results are several strategic initiatives aimed at future growth. Kabra Drugs is planning to enter new business streams, notably the manufacturing of medical equipment. This diversification is complemented by an agreement with MR Franchise to establish 200 channel partners across India, enhancing market presence and distribution capabilities.

The company's proactive approach has resonated with investors, driving its stock price up by nearly 200% in the past year. Furthermore, a proposed name change is under consideration to better align with its evolving business direction, pending necessary approvals. The financial results have undergone limited review by statutory auditors.